<code id='30A6F4DF02'></code><style id='30A6F4DF02'></style>
    • <acronym id='30A6F4DF02'></acronym>
      <center id='30A6F4DF02'><center id='30A6F4DF02'><tfoot id='30A6F4DF02'></tfoot></center><abbr id='30A6F4DF02'><dir id='30A6F4DF02'><tfoot id='30A6F4DF02'></tfoot><noframes id='30A6F4DF02'>

    • <optgroup id='30A6F4DF02'><strike id='30A6F4DF02'><sup id='30A6F4DF02'></sup></strike><code id='30A6F4DF02'></code></optgroup>
        1. <b id='30A6F4DF02'><label id='30A6F4DF02'><select id='30A6F4DF02'><dt id='30A6F4DF02'><span id='30A6F4DF02'></span></dt></select></label></b><u id='30A6F4DF02'></u>
          <i id='30A6F4DF02'><strike id='30A6F4DF02'><tt id='30A6F4DF02'><pre id='30A6F4DF02'></pre></tt></strike></i>

          focus

          focus

          author:comprehensive    Page View:764
          blue sky moderna
          Ruby Wallau for STAT

          Moderna chairman Noubar Afeyan exuded star power earlier this month as he commanded the spotlight at BIO 2023, the industry’s largest convention.

          Basking in the accolades heaped on Moderna’s celebrated Covid-19 vaccine, Afeyan regaled the Boston audience with the company’s origin story and greeted fans who lined up to snap selfies with him. Stuart Cable, a partner in the law firm Goodwin who’s represented Moderna and joined Afeyan on stage, called Moderna “arguably the most successful story in the history of biotechnology.”

          advertisement

          But the Cambridge, Mass.-based company can’t afford to rest on its laurels. Two and a half years after its vaccine liberated tens of millions from pandemic lockdowns — ringing up more than $36 billion in sales so far — Moderna faces a changing business and regulatory environment. Demand for Covid shots is waning, a backlash over drug prices is gaining traction, and questions about its next act loom.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          Telehealth startups turn to complex chronic diseases
          Telehealth startups turn to complex chronic diseases

          MollyFergusonforSTATIfherneurologistmovedtoChina,LaurenStilessaysshe’dfollowhimthere.“There’ssofewdo

          read more
          Trump demands the U.S. pay no more for drugs than other countries … again
          Trump demands the U.S. pay no more for drugs than other countries … again

          EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

          read more

          Kristina Burow of ARCH Venture Partners shares her next big bets STAT

          AlexHogan/STATKristinaBurowhasawell-trainedeye.That’strueofherworkatARCHVenturePartners,oneofthedrug